Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Antisense Pharma Changes Name to Isarna Therapeutics

Published: Monday, September 30, 2013
Last Updated: Monday, September 30, 2013
Bookmark and Share
Development efforts focused on next generation oligonucleotides to treat cancer capitalizing on long-standing experience in TGF-ß.

Antisense Pharma GmbH has changed its name to Isarna Therapeutics GmbH and centralized all of its activities to a single location in Munich, the company announced today at the Sachs 13th Annual Biotech in Europe Investor Forum held in Zurich, Switzerland. The company’s new website is www.isarna-therapeutics.com.

“The name change to Isarna Therapeutics illustrates our new company dynamics combined with our continued leadership in the TGF-β pathway,” explained Dr. Philippe Calais, CEO of Isarna Therapeutics.  “We are currently extending our pipeline to include next-generation oligonucleotides to treat cancer and expect several key near-term events that highlight this momentum.”

Isarna Therapeutics is committed to rapidly advancing a pipeline of next generation oligonucleotides (NGOs) targeting the various isoforms of TGF-β, a family of cytokine proteins that plays a significant role in cancer’s ability to escape immune system detection and promote tumor growth. Based on its unique deciphering of the TGF-β biology, the company has to date amassed an unmatched expertise in discovery and clinical development of oligonucleotides antagonists of the various TGF-β isoforms.  Much of this knowledge is the result of developing its first-generation compound trabedersen for several cancer indications and up to a Phase III clinical trial. The further development of that compound is focused on a Responder Patient Profiling Program (RPPP), aimed at assessing the genetic profile and responder biomarkers of patients suffering from cancer to establish correlations between tumor biology and response to anti-TGF-β oligonucleotides. This unique proprietary program will allow Isarna Therapeutics to select the right patients who will be best suited for treatment not only by trabedersen but also by any of the next generation of TGF-β inhibitors entering clinical development.

“Our goal as a company is to solidify our strengths in the TGF-β isoform family and remain a lean and focused organization capable of rapidly advancing compounds into mid-stage clinical development,” added Dr. Calais.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Antisense Pharma Receives FDA Orphan Drug Designation for Trabedersen
TGF-ß2 inhibitor has gained market exclusivity in the USA for a third aggressive cancer indication.
Friday, October 05, 2012
Antisense Pharma Presents Trabedersen Phase I/II Complete Data at ASCO
Trabedersen demonstrated excellent safety combined with encouraging survival in patients with advanced pancreatic cancer and malignant melanoma.
Tuesday, June 05, 2012
Antisense Pharma Internationalizes Management Board
Dr. Philippe Calais appointed Chief Executive Officer.
Tuesday, May 15, 2012
Antisense Pharma Completes Round of Financing Worth Approximately 8 Million Euro
Effective July, 2011, Antisense Pharma’s founder and CEO, Dr. Karl-Hermann Schlingensiepen, will now be a member of the supervisory board and will focus on the company’s strategy as a consultant.
Thursday, July 07, 2011
Antisense Pharma Receives Approval for Clinical Studies in South Korea and Taiwan in Malignant Brain Tumors
With this approval, the Southeast Asian health agencies KFDA and TFDA have paved the way for the implementation of the pivotal Phase III study SAPPHIRE with the TGF-ß2 inhibitor trabedersen.
Friday, February 18, 2011
Antisense Pharma’s Trabedersen in Malignant Brain Tumors: Phase IIb Data Published in Neuro-Oncology
The investigated drug trabedersen is designed to selectively downregulate the production of TGF-ß2 at the translational level.
Wednesday, November 03, 2010
Antisense Pharma’s Trabedersen in Malignant Brain Tumors: Phase IIb Data Published in Neuro-Oncology
Antisense Pharma have announced that their international, randomized and active-controlled Phase IIb study G004-AP 12009, has been published in the official journal of the American Society for Neuro-Oncology (SNO).
Tuesday, November 02, 2010
Antisense Pharma Obtains IND for Clinical Studies in the USA
The American Department of Health, the FDA, agrees to the use of trabedersen for high-grade glioma.
Tuesday, August 03, 2010
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Genes Underlying Dogs’ Social Ability Revealed
The social ability of dogs is affected by genes that also seem to influence human behaviour, according to a new study from Linköping University in Sweden.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!